Avid Bioservices Inc (CDMO)

[biopharm]

Timeline : Part V

Part V: added Calico licenses technology from acclaimed UCSF laboratory and CALICO collaboration with QB3/Stanford March 24, 2015 and maybe that was kickstarted by Regis Kelly being named UCOP Senior Adviser by Janet Napolitano. Now with Janets ties to Dept. of Homeland Security 2009-2013 (ex DHS Sec. & Republican Tom Ridge just made BOD of Advaxis..) so we must dig deeper there.... because CALICO is not just here for the fun and games of it all since they have as much cash as many Big Pharmas and any collaboration they bring on board is likely a connection to getting Bavituximab into the hands of many as SK has clearly stated. Now more interesting is CALICO and QB3 collaborate just in March 24, 2015 and just months later it is Peregrine and MSK in a full blown collaboration. Art Levinson with ties to both QB3 and MSK

..He currently serves on the Board of Scientific Consultants of the Memorial Sloan Kettering Cancer Center, the Industrial Advisory Board of the California Institute for Quantitative Biosciences (QB3)...
https://en.wikipedia.org/wiki/Arthur_D._Levinson

https://en.wikipedia.org/wiki/Janet_Napolitano

http://link.ucop.edu/2014/12/01/regis-kelly-of-qb3-ucsf-appointed-new-advisor-on-uc-innovation/

Part IV: added May 2, 2013 Foundation Medicine collaboration with MSK. Now you tell me, after Foundation Medicine and MSK have been collaborating ever since May of 2013 and two years later after MSK LIKELY HAVING A PEEK INTO PATTERNS, TRENDS (FUTURE BIOMARKERS??!!), they (MSK) then decide to collaborate with Peregrine Pharmaceuticals on May 29, 2013 for what reasons? maybe more clues given Aug 11

I think we all know the answer to that and we must sit back and let it all play out. I'd rather have all these pieces of the puzzle below and shares on the shelf ready to appreciate in value vs not having any PPHM shares and waiting for the price correction. If you have not read the MSK <> Foundation Medicine article yet from May of 2013 below.. read it. Then you will think twice about all that is happening behind the scenes in Tustin. No way Peregrine partners until they have full operational and commercialization type of leverage, with 2-3x more cash in reserve.

------------------------------------------------------

2006 (STAR CONSORTIUM brings together Memorial Sloan Kettering, Broad Institute of MIT/Harvard, Cold Spring Harbor Laboratory, The Rockefeller University and Weill Cornell Medical College)
https://www.mskcc.org/research-areas/programs-centers/starr-consortium

Jan 8, 2013 (Bill Gates invests in Foundation Medicine)
http://www.boston.com/businessupdates/2013/01/08/bill-gates-invests-foundation-medicine-which-uses-genome-data-for-cancer-diagnostics/BtipX6STIA5prjmrjJkHzI/story.html

May 2, 2013 - Foundation Medicine and Memorial Sloan
-Kettering Cancer Center Announce Partnership to Advance Patient Care in Hematologic Cancers
http://www.foundationmedicine.com/pdf/news-releases/2013_05_02_FMI_MSKCC_FINAL.pdf

Sept 18, 2013 (Art Levinson becomes CEO @CALICO)
http://googlepress.blogspot.com/2013/09/calico-announcement.html

Dec 5, 2013 -A pioneering effort to speed the development of novel immunotherapies for cancer drew national headlines this week with the announcement of Memorial Sloan Kettering’s partnership in a newly formed biotechnology company called Juno Therapeutics.
https://www.mskcc.org/blog/new-biotech-startup-will-pit-immune-system-against

Dec 10, 2013 -Peregrine bouncing back with new plan after the sabotage...adds 4 top KOL's Dmitry Gabrilovich, Scott Antonia, David Carbone and Hakan Mellstedt.
http://investorshub.advfn.com/boards/replies.aspx?msg=92957339

April 6, 2014 - Patient deaths force MSK to hit the brakes on engineered T cell cancer study (months later Hal Barron brought on board @Juno to redirect the program)
http://www.fiercebiotech.com/story/memorial-sloan-kettering-hits-brakes-engineered-t-cell-cancer-study/2014-04-06

May 21, 2014 (Broad Institute moves 800 into new bldg..)
http://www.bostonglobe.com/business/2014/05/20/broad-institute-moves-researchers-new-building/0UHZcowC1u0W74lsJZ7SYI/story.html#

July 22, 2014(Broad Institute rec'd $650M from Ted Stanley)
https://www.bostonglobe.com/lifestyle/health-wellness/2014/07/21/broad-institute-receives-million-commitment-for-psychiatric-research/EkpKRskBV9tuTd09mLT39H/story.html

Sept 3, 2014 (CALICO and Abbvie announce novel collaboration)
http://www.calicolabs.com/news/2014/09/03/

Sept 4, 2014 (Art resigns from BOD @Roche but look above, a day after CALICO and Abbvie deal!..Roche pi$$ed)
http://www.reuters.com/article/2014/09/04/roche-moves-idUSL5N0R50UF20140904

Sept 11, 2014 (CALICO and UTSWM 2M)
http://www.utsouthwestern.edu/newsroom/news-releases/year-2014/sept/calico-collaboration.html

Sept 16, 2014 (CALICO UTSWM neuro..compounds)
http://www.fiercebiotechresearch.com/story/googles-calico-acquires-ut-southwestern-compounds-neurodegenerative-disorde/2014-09-16

Oct 1, 2014 -Juno Appoints Hal Barron, M.D. to Board of Directors
Juno Therapeutics, Inc. today announced the appointment of Hal Barron, M.D., President of Research & Development at Calico, to its Board of Directors. (Hal) will bring valuable insights to our team as we work to bring our CAR and TCR product candidates to patients and disrupt the treatment of cancer,” said Juno CEO Hans Bishop. (Hal advises Juno/MSK they need PS Targeting?! : )
https://junotherapeutics.com/juno-appoints-hal-barron-m-d-to-board-of-directors/

Dec 1, 2014 - Regis Kelly appointed new advisor on UC innovation (CALICO and QB3 Director Regis Kelly sign collaboration just 3 months later on March 24, 2015)
http://link.ucop.edu/2014/12/01/regis-kelly-of-qb3-ucsf-appointed-new-advisor-on-uc-innovation/

Feb 4&6, 2015 IHUB posts: (re: p.29 Foundation = Foundation Medicine which Roche was already in talks with to control)

page#29 There is an entire public-private partnership at Foundation..

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=110532753

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=110614889

March 17, 2015 (CALICO and Broad Institute and CALICO CEO Art Levinson on the BOD of Broad Institute)
https://www.broadinstitute.org/news/6633
http://www.broadfoundation.org/asset/1165-091008broadinstituteboardrelease.pdf

March 24, 2015 (CALICO and QB3) Google's Calico widens its R&D net with QB3 partnership
..And that's where QB3 fits in. Short for California Institute for Quantitative Biosciences, the consortium is a translational medicine-focused outfit uniting more than 250 scientists at UC San Francisco, UC Berkeley and UC Santa Cruz. Alongside VC affiliate Mission Bay Capital, the institute has helped launch hundreds of startups from the university's ecosystem, and QB3 is hoping to apply that same mutually beneficial model in its work with Calico, Director Regis Kelly said.

"We are all aging, and we will all benefit from the discoveries made in this program and the therapies that will result," Kelly said in a statement. "... Tackling aging requires a translational perspective and multidisciplinary approach that QB3 is well-placed to coordinate."
http://www.fiercebiotech.com/story/googles-calico-widens-its-rd-net-qb3-partnership/2015-03-24
http://www.calicolabs.com/news/2015/03/24/

March 31, 2015 Calico licenses technology from acclaimed UCSF laboratory
http://www.calicolabs.com/news/2015/03/31/

April 7, 2015 (Roche now controls Foundation Medicine)
http://investors.foundationmedicine.com/releasedetail.cfm?releaseid=905240

May 29, 2015 (Memorial Sloan Kettering and Peregrine Pharmaceuticals collaborate) *added note CALICO CEO Art Levinson on the scientific advisory board here at MSK and possibly a sign of things to come between Peregrine and a CALICO announcement
http://ir.peregrineinc.com/releasedetail.cfm?ReleaseID=915472

..He currently serves on the Board of Scientific Consultants of the Memorial Sloan Kettering Cancer Center, the Industrial Advisory Board of the California Institute for Quantitative Biosciences (QB3)...
https://en.wikipedia.org/wiki/Arthur_D._Levinson

June 22, 2015 IMS Health and Foundation Medicine Announce Collaboration to Optimize Targeting of Precision Therapies in Oncology

“This collaboration with Foundation Medicine extends our Real-World Evidence platform – uniquely linking claims, EMR and biomarker data at the anonymous patient level to drive a complete understanding of the oncology patient journey and improve clinical development and commercialization strategies.”

http://www.imshealth.com/portal/site/imshealth/menuitem.c76283e8bf81e98f53c753c71ad8c22a/?vgnextoid=e9c7e8b32370e410VgnVCM1000000e2e2ca2RCRD&vgnextchannel=5ec1e590cb4dc310VgnVCM100000a48d2ca2RCRD&vgnextfmt=default

..and as a bonus just why did Art Levinson leave NGM: (I know... too many puzzle pieces for some to follow..)
http://www.ngmbio.com/about/board-of-directors/